Search Result

Results for "

bone marrow macrophages

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Akt (2) Apoptosis (2) Autophagy (2) c-Fms (3) Cathepsin (1) Ferroptosis (1) GLUT (1) Glutathione Peroxidase (1) Glutathione S-transferase (1) HDAC (1) Heme Oxygenase (HO) (1) IFNAR (1) Interleukin Related (2) Keap1-Nrf2 (1) NF-κB (4) NO Synthase (6) NOD-like Receptor (NLR) (3) Nuclear Factor of activated T Cells (NFAT) (2) OAT (1) p38 MAPK (3) PD-1/PD-L1 (1) Phosphatase (1) Prostaglandin Receptor (2) RANKL/RANK (5) Reference Standards (2) SOD (1) STING (1) TGF-beta/Smad (1) TNF Receptor (2) Toll-like Receptor (TLR) (3) Trace Amine-associated Receptor (TAAR) (1) URAT1 (1)
By Research Areas:	Cancer (10) Infection (6) Inflammation/Immunology (13) Metabolic Disease (7) Neurological Disease (5)

By Targets:

ADC Payload (1)

Akt (2)

Apoptosis (2)

Autophagy (2)

c-Fms (3)

Cathepsin (1)

Ferroptosis (1)

GLUT (1)

Glutathione Peroxidase (1)

Glutathione S-transferase (1)

HDAC (1)

Heme Oxygenase (HO) (1)

IFNAR (1)

Interleukin Related (2)

Keap1-Nrf2 (1)

NF-κB (4)

NO Synthase (6)

NOD-like Receptor (NLR) (3)

Nuclear Factor of activated T Cells (NFAT) (2)

OAT (1)

p38 MAPK (3)

PD-1/PD-L1 (1)

Phosphatase (1)

Prostaglandin Receptor (2)

RANKL/RANK (5)

Reference Standards (2)

SOD (1)

STING (1)

TGF-beta/Smad (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (3)

Trace Amine-associated Receptor (TAAR) (1)

URAT1 (1)

By Research Areas:

Cancer (10)

Infection (6)

Inflammation/Immunology (13)

Metabolic Disease (7)

Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W018643

Ferulic acid methyl ester 1 Publications Verification Methyl ferulate	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology Cancer
Ferulic acid methyl ester (Methyl ferulate) is a derivative of ferulic acid, isolated from Stemona tuberosa, with anti-inflammatory and antioxidant properties . Ferulic acid methyl ester is a cell membrane and brain permeable compound, shows free radical scavenging ability, used in the research of neurodegenerative disorders . Ferulic acid methyl ester inhibits COX-2 expression, blocks p-p38 and p-JNK in primary bone marrow derived-macrophages .

HY-W008634

Bropirimine 2 Publications Verification U-54461; U-54461S; PNU-54461	Toll-like Receptor (TLR)	Cancer
Bropirimine (U-54461; U-54461S; PNU-54461) is an orally active TLR7 agonist. Bropirimine inhibits RANKL-induced osteoclast differentiation of mouse bone marrow-derived macrophages (BMMs). Bropirimine exhibits dose-dependent direct inhibitory effects on colony formation of cultured KK-47 and 724 cells. Bropirimine can be used for the study of cancers and bone metabolic disorders such as osteoporosis .

HY-N8698

Picein 1 Publications Verification	SOD Ferroptosis Keap1-Nrf2 Heme Oxygenase (HO) Glutathione Peroxidase	Neurological Disease Metabolic Disease Inflammation/Immunology
Picein is an antioxidant and anti-inflammatory agent. Picein can be isolated from the leaves of Picrorhiza kurroa. Picein reduces MDA levels and increases the levels of SOD, GPX and TAC. Picein alleviates oxidative stress and promotes bone regeneration in osteoporotic bone defects by inhibiting Ferroptosis (via activation of the Nrf2/HO-1/GPX4 pathway). Picein prevents scopolamine (HY-N0296)-induced passive avoidance memory impairment in rats. Picein can be used in research related to osteoporotic bone defects and Alzheimer's disease .

HY-12700

RO5256390 3 Publications Verification	Trace Amine-associated Receptor (TAAR)	Neurological Disease
RO5256390 is an orally effective trace amine associated receptor 1 (TAAR1) agonist. RO5256390 exhibits pro-cognitive and antidepressant-like properties in rodent and primate models, showing similar brain activation patterns to Olanzapine (HY-14541). RO5256390 blocks compulsive overeating behavior in rats. RO5256390 can inhibit ATP (HY-B2176)-induced TNF secretion in mouse bone marrow-derived macrophages .

HY-145961

TLR7 agonist 4	Toll-like Receptor (TLR) TNF Receptor	Cancer
TLR7 agonist 4 is a TLR7 agonist with pro-inflammatory cytokine-stimulating activity. TLR7 agonist 4 modulates TLR7 activity to stimulate the production of pro-inflammatory cytokines. TLR7 agonist 4 stimulates mouse bone marrow-derived macrophages to produce the pro-inflammatory cytokine TNFα. TLR7 agonist 4 can be conjugated with antibodies to form conjugates. TLR7 agonist 4 is applicable to cancer research .

HY-147615

CSF1R-IN-12	c-Fms	Cancer
CSF1R-IN-12 (compound 1) is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-12 has the potential for the research of cancer diseases .

HY-174156

Y2641	RANKL/RANK TNF Receptor	Inflammation/Immunology
Y2641, a etrahydro-β-carboline derivative, is an orally active dual RANKL/TNF-α inhibitor with K_d values of 3.984 μM and 18.59 μM for RANKL and TNF-α, respectively. Y2641 inhibits RANKL-induced osteoclastogenic and has anti-inflammatory and cartilage destruction. Y2641 can be used for study of osteoarthritis .

HY-102065

SC-19220	Prostaglandin Receptor RANKL/RANK	Metabolic Disease
SC-19220 is a prostaglandin E₂ receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption .

HY-P10383

SPSB2-iNOS inhibitory cyclic peptide-1	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

HY-173070

TLR7 agonist 29	Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 ADC Payload	Inflammation/Immunology Cancer
TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC₅₀ of 5.2 nM for human TLR7 (EC₅₀ for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC .

HY-175645

NLRP3/URAT1-IN-1	NOD-like Receptor (NLR) URAT1 Interleukin Related OAT GLUT	Metabolic Disease Inflammation/Immunology
NLRP3/URAT1-IN-1 is an orally active double inhibitor of NLRP3 and URAT1 (IC₅₀ = 3.81 μM). NLRP3/URAT1-IN-1 inhibits IL-1β release in LPS (HY-D1056) and ATP-stimulated mouse bone marrow-derived macrophages (BMDMs), with an IC₅₀ of 2.61 μM. NLRP3/URAT1-IN-1 reduces serum uric acid (SUA) and alleviates liver/kidney damage in mice with acute hyperuricemia (HUA). NLRP3/URAT1-IN-1can be used for the study of gout and hyperuricemia .

HY-169703

SPA0355 1 Publications Verification	RANKL/RANK p38 MAPK Akt NF-κB	Inflammation/Immunology
SPA0355 is a thiourea derivative that has antioxidant and anti-inflammatory properties. SPA0355 inhibits the RANKL (receptor activator of nuclear factor κB ligand) induced osteoclast formation in primary bone marrow-derived macrophages. SPA0355 also suppresses the activation of the MAPKs, Akt, and NF-κB pathways. Additionally, SPA0355 promotes osteoblast differentiation, increases alkaline phosphatase activity, and enhances mineral nodule formation. SPA0355 can protect ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it useful for studying postmenopausal osteoporosis .

HY-151569

SAHA-OH	HDAC Apoptosis	Inflammation/Immunology
SAHA-OH is a selective HDAC6 inhibitor (IC₅₀=23 nM), shows a 10- to 47-fold selectivity for HDAC6 compared to HDAC 1, 2, 3, and 8. SAHA-OH shows anti-inflammatory activity, and attenuates macrophage apoptosis .

HY-131040

NLRP3-IN-NBC6	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC₅₀= 574 nM) that acts independently of Ca ²⁺. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs) .

HY-W615446

GSTO1-IN-3	Glutathione S-transferase Interleukin Related	Inflammation/Immunology Cancer
GSTO1-IN-3 is a potent GSTO1-1 inhibitor with an IC₅₀ of 0.11 μM, and shows selectivity over GSTO2-2, GSTA1-1 and GSTP1-1 (IC₅₀ > 100 μM). GSTO1-IN-3 enhances the cytotoxicity of Cisplatin (HY-17394) against human breast cancer cells. GSTO1-IN-3 inhibits IL-1β release in mouse bone marrow-derived macrophage (BMDM) cells. GSTO1-IN-3 attenuates inflammation in mice. GSTO1-IN-3 can be used for breast cancer and inflammation research .

HY-168089

NLRP3-IN-49	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-49 (compound Z48) is a potent and specific NLRP3 inhibitor (IC₅₀=0.26 μM in THP-1 cells, IC₅₀=0.21 μM in mouse bone marrow macrophages). NLRP3-IN-49 can directly bind to NLRP3 protein (K_d=1.05 μM), effectively preventing the assembly and activation of NLRP3 inflammasome, thereby exhibiting anti-inflammatory properties. NLRP3-IN-49 can be used in the study of inflammatory bowel disease .

HY-N11494

Dauricumine	NF-κB	Others
Dauricumine is a chlorinated alkaloid that inhibits NF-κB ligand-induced differentiation of mouse bone marrow-derived macrophages into multinucleated osteoclasts .

HY-N12507

Eupenicisirenin C	STING NF-κB	Others
Eupenicisirenin C (compound 1) is a sirenin derivative. Eupenicisirenin C has strong NF-κB inhibitory activities. Eupenicisirenin C suppresses effects on cGAS-STING pathway. Eupenicisirenin C inhibits RANKL-induced osteoclast differentiation in bone marrow macrophage cells .

HY-P10384A

SPSB2-iNOS inhibitory cyclic peptide-2 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-2 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-2 (HY-P10384). SPSB2-iNOS inhibitory cyclic peptide-2 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 TFA is reduction-resistant and oxidatively stable .

HY-P10385A

SPSB2-iNOS inhibitory cyclic peptide-3 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-3 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-3 (HY-P10385). SPSB2-iNOS inhibitory cyclic peptide-3 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 7 nM .

HY-P10384

SPSB2-iNOS inhibitory cyclic peptide-2	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-2 (Compound CP2) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 is reduction-resistant and oxidatively stable .

HY-P10385

SPSB2-iNOS inhibitory cyclic peptide-3	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-3 (Compound CP3) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 7 nM .

HY-147616

CSF1R-IN-13	c-Fms	Cancer
CSF1R-IN-13 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-13 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 32) .

HY-P10383A

SPSB2-iNOS inhibitory cyclic peptide-1 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-1(HY-P10383). SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

HY-147617

CSF1R-IN-14	c-Fms	Cancer
CSF1R-IN-14 is an isoindolinone derivative compound. CSF1R-IN-14 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-14 has the potential for the research of cancer diseases (extracted from patent WO2019134662A1, compound 1) .

HY-N11775

Eudebeiolide B Plebeiolide D	NF-κB Akt Nuclear Factor of activated T Cells (NFAT) Phosphatase	Metabolic Disease
Eudebeiolide B is a compound that can be isolated from Salvia plebeia R. Br. Eudebeiolide B inhibits osteoclastogenesis by regulating RANKL-induced NF-κB, c-Fos and calcium signaling. Eudebeiolide B can be used for osteoclast-related diseases research .

HY-182757

Y1693	RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Cathepsin	Metabolic Disease Inflammation/Immunology
Y1693 is an orally active RANKL inhibitor with a K_d of 5.03 μM for hRANKL. Y1693 inhibits the activation of the downstream c-fos/NFATc1 signaling pathway by blocking its interaction with RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation and bone resorptive activity, while downregulating the mRNA and protein expressions of TRAP, cathepsin K, c-fos and NFATc1. Y1693 shows no obvious cytotoxicity to bone marrow-derived macrophages and osteoclast precursor cells, and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research related to osteoporosis and periodontal diseases .

HY-N18265

(4E,6E,12E)-3-Hydroxy-4,6,12-tetradecatriene-8,10-diyn-1-yl acetate	Others	Metabolic Disease
(4E,6E,12E)-3-Hydroxy-4,6,12-tetradecatriene-8,10-diyn-1-yl acetate is a polyacetylene found in rhizomes of Atractylodes chinensis. (4E,6E,12E)-3-Hydroxy-4,6,12-tetradecatriene-8,10-diyn-1-yl acetate inhibits RANKL-induced osteoclast differentiation. (4E,6E,12E)-3-Hydroxy-4,6,12-tetradecatriene-8,10-diyn-1-yl acetate can be used for the research of osteoporosis .

HY-124693

DB1055	Apoptosis	Cancer
DB1055 is a HOXA9 inhibitor that competes with HOXA9 binding to DNA (blocking its DNA interaction activity). DB1055 induces in vitro cell growth reduction, cell apoptosis, and differentiation in human acute myeloid leukemia (AML) cells. DB1055 leads to monocyte-to-macrophage differentiation and exhibits antileukemic activities in a human THP-1 AML in vivo model. DB1055 does not impact human CD34⁺ bone marrow cells. DB1055 can be used for the research of acute myeloid leukemia^[1].

HY-W018643R

Ferulic acid methyl ester (Standard) Methyl ferulate (Standard)	p38 MAPK Reference Standards Autophagy	Neurological Disease Inflammation/Immunology Cancer
Ferulic acid methyl ester (Standard) is the analytical standard of Ferulic acid methyl ester (HY-W018643). This product is intended for research and analytical applications. Ferulic acid methyl ester (Methyl ferulate) is a derivative of ferulic acid, isolated from Stemona tuberosa, with anti-inflammatory and antioxidant properties . Ferulic acid methyl ester is a cell membrane and brain permeable compound, shows free radical scavenging ability, used in the research of neurodegenerative disorders . Ferulic acid methyl ester inhibits COX-2 expression, blocks p-p38 and p-JNK in primary bone marrow derived-macrophages .

HY-102065R

SC-19220 (Standard)	Reference Standards Prostaglandin Receptor RANKL/RANK	Metabolic Disease
SC-19220 (Standard) is the analytical standard of SC-19220 (HY-102065). This product is intended for research and analytical applications. SC-19220 is a prostaglandin E₂ receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption .

HY-P11753

IKVAVC	TGF-beta/Smad	Neurological Disease Inflammation/Immunology
IKVAVC is a derivative peptide of IKVAV with an artificially added cysteine (Cys) at its C-terminus. IKVAVC retains all the biological activities of the original IKVAV, mainly acting as a neural adhesion/differentiation signaling peptide, and is equipped with an engineered linker arm that enables covalent conjugation to molecular materials. IKVAV inhibits the migration and activation of fibroblasts, downregulates the TGF-β1 signaling pathway and endoplasmic reticulum stress, and promotes nerve repair. IKVAV regulates the phenotype of macrophages, shifting them from the pro-inflammatory M1 type to the pro-reparative M2 type .

Cat. No.	Product Name

HY-L174

Macrophage Related Compound Library	264 compounds
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance. MCE designs a unique collection of 264 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

Macrophage Related Compound Library

264 compounds

Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance.

MCE designs a unique collection of 264 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

Cat. No.	Product Name	Target	Research Area